Oppenheimer Maintains Outperform on Design Therapeutics, Raises Price Target to $21
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Oppenheimer analyst Kostas Biliouris maintains Design Therapeutics (NASDAQ:DSGN) with a Outperform and raises the price target from $18 to $21.
Oppenheimer analyst Kostas Biliouris maintains Design Therapeutics (NASDAQ:DSGN) with a Outperform and raises the price target from $18 to $21.